2019-07-23

Press releases regulatory

2cureX announces that patients are successfully being enrolled in the IndiTreat® pancreatic cancer trial

2cureX AB (“2cureX”, NASDAQ: 2CUREX), a clinical-stage company that has developed the IndiTreat® test allowing individualization of cancer treatment, hereby...

2019-06-27

Press releases regulatory

Last day of trading in BTA 1 in 2cureX AB

In May 2019, 2cureX AB (“2cureX”) conducted a rights issue of shares in which the general public was given the...

2019-06-25

Press releasesPress releases regulatory

Change of Certified Adviser to Svensk Kapitalmarknadsgranskning AB

2cureX AB (“2cureX”) has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (“SKMG”) regarding Certified Adviser services. SKMG will be...

2019-06-20

Press releases regulatory

2cureX appoints Dr. Med. Henrik Harling as Chief Medical Officer

2cureX AB (NASDAQ: 2CUREX), a clinical-stage company that has developed the IndiTreat® test allowing individualization of cancer treatment, hereby announces...

2019-05-28

Press releases regulatory

Communique from the Annual General Meeting in 2cureX AB (publ)

Today, on May 28th, 2019, the Annual General Meeting (“AGM”) was held in 2cureX AB (publ). Below follows a summary...

2019-05-28

Press releases regulatory

Significantly oversubscribed rights issue in 2cureX AB

On May 23, 2019, the subscription period ended in 2cureX AB’s (“2cureX”) rights issue prior to the market launch of...